Clinical trial
VX-853 in Treating Patients With Solid Tumors Who Are Receiving Liposomal…
NCT00004030 · Georgetown University, Other · Completed
Key facts
| NCT number | NCT00004030 |
|---|---|
| Title | VX-853 in Treating Patients With Solid Tumors Who Are Receiving Liposomal Doxorubicin |
| Official title | A Phase I/II Study of the Pharmacokinetics, Tolerability and Safety of Administration of VX-853 to Patients Receiving Single Agent Therapy With Doxorubicin HCI |
| Lead sponsor | Georgetown University, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug |
| Interventions | VX-853, pegylated liposomal doxorubicin hydrochloride |
| Enrollment | 45 |
| Start date | Mar 1, 1996 |
| Primary completion | Jan 1, 2001 |
| Completion | Jan 1, 2001 |
| First posted | May 25, 2004 |
| Last update posted | Mar 24, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: